‘Omalizumab changed my life’: a patient perspective on solar urticaria-Reference-Cited by-同舟云学术

‘Omalizumab changed my life’: a patient perspective on solar urticaria

Published:2024-03-16 Issue:8 Volume:49 Page:935-936
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Parkin Donna¹,Ling Tsui C¹²,Ayer Jean¹²,Rhodes Lesley E¹²,Rutter Kirsty J¹²^ORCID

Affiliation:

1. Photobiology Unit, Department of Dermatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Greater Manchester , UK

2. The Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre , Manchester , UK

Abstract

This patient perspective on solar urticaria demonstrates some of the key clinical characteristics and impact of solar urticaria, as well as a first-hand account of the transformative potential of omalizumab therapy. The clinicians’ comment reviews clinical features and aspects of diagnosis and management.

Funder

NIHR Manchester Biomedical Research Centre

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llae074/57419090/llae074.pdf

Reference5 articles.

1. Quality of life and psychological impact in the photodermatoses: a systematic review;Rutter;Br J Dermatol,2020

2. Pathogenesis of solar urticaria: classic perspectives and emerging concepts;McSweeney;Exp Dermatol,2022

3. Solar urticaria in 145 patients: assessment of action spectra and impact on quality of life in adults and children;Haylett;Photodermatol Photoimmunol Photomed,2018

4. PDO4 Real-life experience of Scottish patients with idiopathic solar urticaria;McMullan;Br J Dermatol,2023

5. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria;Zuberbier;Allergy,2022